Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
Authors
Chao Yin
Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
Chao Yin , John Marshall , Laura Macke , Kerrie Bouker , Aiwu Ruth He , Benjamin Adam Weinberg , Louis M. Weiner , Hongkun Wang , Nabeel Badri , Nigel Biswas-Baldwin , Frank Hoke , Hagop Youssoufian , Iman El-Hariry , Marcus Smith Noel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04292743
DOI
10.1200/JCO.2022.40.4_suppl.581
Abstract #
581
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang
Poster
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran